Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
(NASDAQ:IMVT) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today shared an abstract with six-month off-treatment data in uncontrolled Gravesâ disease (GD) patients treated with batoclimab for 24 weeks, to be presented at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
Related Questions
What is the anticipated regulatory timeline and likelihood of FDA approval for batoclimab following these sixâmonth offâtreatment remission results?
How large is the addressable market for uncontrolled Graves' disease and what market share could Immunovant realistically capture with a treatmentâfree remission therapy?
How does batoclimab's efficacy, safety, and durability data compare to existing therapies and competing pipeline candidates for Graves' disease?